Anemia Clinical Trial
NCT number | NCT02176759 |
Other study ID # | Rice_SFePP |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | June 25, 2014 |
Last updated | December 23, 2014 |
Start date | September 2014 |
Ferric pyrophosphate (FePP) is a water-insoluble, food grade iron compound used to fortify
rice, infant cereals and chocolate-drink powders as it causes no organoleptic changes to the
food vehicle. However, it is only of low absorption in man. Therefore, strategies to enhance
the bioavailability of FePP, such as adding citrate or decreasing the particle size of FePP
need to be investigated. The primary objectives of the present study are: 1) to test whether
the presence of citrate in iron fortified rice with FePP results in higher iron
bioavailability, and 2) to test whether the presence of citrate in the rice grain during the
extrusion and cooking process results in higher iron bioavailability compared with
iron-fortified rice where citrate has been added shortly before consumption. As a secondary
objective the investigators will compare the absorption from different FePP combinations
with a reference meal fortified with ferrous sulphate. The investigator hypothesize that the
addition of citrate enhances iron absorption and that the positive effect is greater when
the citrate is added during the extrusion.
The investigator will conduct an iron absorption study in 20 women, 18 to 45 years old to
evaluate the iron bioavailability from extruded rice fortified with 1) regular FePP, 2)
regular FePP and citrate (both extruded into the rice kernels), 3) regular FePP and citrate
added at the time of consumption, and 4) from normal rice fortified with ferrous sulphate at
the time of consumption. Iron absorption will be measured as erythrocyte incorporation of
stable iron isotopes at least 14 days after the administration of the isotopically labelled
test meals. The iron absorption from the different meals within the same participant will be
compared by repeated-measures ANOVA followed by a Bonferroni corrected pairwise comparison.
The present study will provide important data where iron bioavailability from rice is
accurately and directly measured using stable isotopic labels as absorption tracers. This
direct data can be used to base decisions on the level of fortification, can potentially
reduce costs and optimize iron delivery to the targeted population in iron fortification
programs.
Status | Completed |
Enrollment | 20 |
Est. completion date | |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Female, 18 to 45 years old - Normal body Mass Index (18.5 - 25 kg/m2) - Body weight < 65 kg - Signed informed consent Exclusion Criteria: - Pregnancy (assessed by a pregnancy test) - Lactating - Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) - Continuous/long-term use of medication during the whole study (except for contraceptives) - Consumption of mineral and vitamin supplements within 2 weeks prior to 1st meal administration - Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months - Earlier participation in a study using Fe stable isotopes or participation in any clinical study within the last 30 days - Participant who cannot be expected to comply with study protocol (e.g. not available on certain study appointments) |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Switzerland | Human Nutrition Laboratory | Zurich |
Lead Sponsor | Collaborator |
---|---|
Swiss Federal Institute of Technology |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the isotopic ratio of iron in blood at week 2 | The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes. | baseline, 2 weeks | No |
Primary | Change from week 2 in the isotopic ratio of iron in blood at week 4 | The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes. | 2 weeks, 4 weeks | No |
Primary | Change from week 4 in the isotopic ratio of iron in blood at week 6 | The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes. | 4 weeks, 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |